Hologic (HOLX) Buy Reiterated a Needham & Company Post Q2 on 'Encouraging' Return to Rev Growth

May 1, 2014 7:15 AM

Needham & Company analyst Mike Matson reiterated a Buy rating and $26 price target on Hologic (NASDAQ: HOLX) following Q2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found